MSRA and non-small cell lung carcinoma: The liposomes had the antitumor ability to reprogram the protumor TAM2 toward antitumor TAM1 and modulate the ROS/methionine sulfoxide reductase A (MsrA)/EGFRT790M transduction axis; thus resensitizing EGFRT790M‐associated Gef‐resistant NSCLC therapy.[126]